Recludix Pharma, Inc., a leading company in the discovery of inhibitors for challenging targets in inflammatory disease and cancer, has announced a strategic collaboration with Sanofi US (NASDAQ: SNY) to develop and market innovative oral small molecule STAT6 inhibitors. The goal of this collaboration is to advance the development of a preclinical oral STAT6 inhibitor for patients suffering from immunological and inflammatory diseases. As part of the agreement, Recludix will receive $125 million in upfront payments, as well as potential milestone payments exceeding $1.2 billion in the future. Additionally, Recludix may also receive double-digit royalties on sales.
During the partnership, Recludix will be responsible for leading research and development activities until Phase 2 clinical trials begin. After that point, Sanofi will take over global clinical development and commercialization responsibilities. Furthermore, Recludix has the option to equally participate in profit/loss sharing within the United States.
STAT6 is believed to play a crucial role in various dermatological and respiratory diseases. By targeting STAT6, Recludix's approach holds significant potential for addressing multiple immunological and